期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

冠心病PCI围术期抗凝及二级预防的用药分析 被引量：1

下载PDF
导出
摘要 经皮冠状动脉干预（PCI）是一种创伤性治疗手段,气囊扩张使得斑块部位的内膜撕裂,斑块内容物尤其组织因子暴露于血液;置放的支架是一种异物;血管穿刺和导管侵入也会激活血液形成血栓,因此PCI围术期抗凝是必须的。
作者 范广建 刘强 朱卫江
机构地区 新疆维吾尔自治区人民医院药学部
出处 《新疆医学》 2011年第10期159-163,共5页 Xinjiang Medical Journal
关键词 围术期 PCI 用药分析 二级预防 抗凝 冠心病 经皮冠状动脉干预 创伤性治疗
分类号 R654.2 [医药卫生—外科学]
  • 相关文献

参考文献11

  • 1Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for re- duction of periprocedural myocardial infartion in patients undergoing coronary intervention:results from the ARMYDA -2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angio- plasty) study [ J ]. Circulation, 2005 ; 26 ( 16 ) : 2009 - 2106.
  • 2赵水平.冠心病二级预防中的降脂治疗[J].中国医药导刊,2000,2(1):34-36. 被引量：12
  • 3胡大一,孙艺红.优化的药物治疗是冠心病二级预防的基石[J].中华内科杂志,2007,46(6):442-443. 被引量：42
  • 4Smith SC J r, Feldman TE, Hirshfeld JW J r, et al. ACC/AHA/SCA1 2005 GUideline Update for Percutaneous Coronary Imervention - summary article : a report of the American College of Car- diology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writ- ing Commitree to Update the 2001 Guidelines for Percutaneous Coronary Intervention ) [ J ]. Circulation,2006 ; 113 ( 1 ) : 156 - 175.
  • 5Steinhubl SR, Berger PB, Mann JT 3rd, et al. For the CREDO investigatiors, early and sus- tained dual oral antiplatelet therapy following percutaneous coronary intervention: a random-ized controlled trial [ J ]. JAMA, 2002, 288 (19) :2411 -2420.
  • 6Mehta SR, Yusufs, Peter R J, et al. Effects of pre- treatment With Clop - idogrel and aspirin fol- lowed by longterm therapy in patients undergo- ing percutaneous coronary intervention:the PCI - CURE stydy[J]. Lancet,2001 ; 358 (4) :527 -533.
  • 7CHEN Ji-lin CHEN Jue QIAO Shu-bin GUO Yuan-lin WU Yong-jian DAI Jun YUAN Jin-qing QIN Xue-wen YANG Yue-jin GAO Run-lin.A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease[J].Chinese Medical Journal,2006(5):355-359. 被引量：19
  • 8ColletJP, Montalescot coronary intervention aparin pretreatment angina pectoris [ J ]. - 663. G, LisonL. Percutaneous after subcutaneous enOx- in patients with unstable Circulation ,2001 ; 103:658.
  • 9Pasceri V, Patti G, NuscaA, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty ) study [ J]. Circulation,2004 ; 110:674 - 678.
  • 10Noordzij PG, Poldermans D, Schouten O, et al. Beta -blocker sandstatinsare individually asso- ciated with reduced mortality in patients under- going noncardiac, nonvascular surgery [ J ]. Coron Artery Dis. 2007Feb ; 18 ( 1 ) :67 - 72.

二级参考文献11

  • 1方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量：3067
  • 2Choussat R,Montalescot G,Collet JP,Vicaut E,Ankri A,Gallois V,et al.A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention[].Journal of the American College of Cardiology.2002
  • 3Goodman SG,Cohen M,Bigonzi F,Gurfinkel EP,Radley DR,Le Iouer V,et al.Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparion for unstable coronary artery disease:one-year results of the ESSENCE study.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave CORONARY Events[].Journal of the American College of Cardiology.2000
  • 4Cohen M,Demers C,Gurfinkel EP,Turpie AG,Fromell GJ,Goodman S,et al.A comparison of low-molecular- weight heparin with unfractionated heparin for unstable coronary artery disease.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group[].The New England Journal of Medicine.1997
  • 5Montalescot G,Collet JP,Tanguy ML,Ankri A,Payot L,Dumaine R,et al.Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin[].Circulation.2004
  • 6Argenti D,Hoppensteadt D,Heald D,Jensen B,Fareed J.Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy[].American Journal of Therapeutics.2003
  • 7Martin JL,Fry ET,Sanderink GJ,Atherley TH,Guimart CM,Chevalier PJ,et al.Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study[].Catheterization and Cardiovascular Interventions.2004
  • 8Moliterno DJ,Hermiller JB,Kereiakes DJ,Yow E,Applegate RJ,Braden GA,et al.A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention.Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study[].Journal of the American College of Cardiology.2003
  • 9Kereiakes DJ,Montalescot G,Antman EM,Cohen M,Darius H,Ferguson JJ,et al.Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus[].American Heart Journal.2002
  • 10Collet JP,Montalescot G,Golmard JL,Tanguy ML,Ankri A,Choussat R,et al.Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes[].American Heart Journal.2004

共引文献66

同被引文献10

  • 1韩雅玲.中国经皮冠状动脉介入治疗指南2012(简本)[J].中国医学前沿杂志（电子版）,2012,4(12):50-59. 被引量：133
  • 2DI SCIASCIO G L,PAq33 G,PASCERI V,et al.Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy:results of the ARMYDA-4 RELOAD (antiplatelet therapy for reduction of myocardial damage during angioplasty ) randomized trial [j] .Eur Heart,2010,31 (11):1337-1343.
  • 3STEINHUBL S R, BERGER P B, BRENNAN D M, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention [J] .J Am Coil Cardiol,2006,47(5) :939-943.
  • 4GURBEL P A, BLIDEN K P, BUTLER K, et al.Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versusclopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study [ J ]. Circulation, 2009,120 (25) : 2577- 2585.
  • 5AMSERDAM E A, WENGER N K, BRINDIS R G, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American college of cardiology/American heart association task force on practice guidelines [ J ] .J Am Coil Cardiol,2014,64(24) : 139-228.
  • 6LEVINE G N,BATES E R,BLANKENSHIP J C,et al,2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention.a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and Interventions[ J ] .J Am Coil Cardiol,2011,58(24) :44- 122.
  • 7SILVAIN J, BEYGUI F, BARTHELEMY O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention : systematic review and meta-analysis[J].BMJ,2012,344:553.
  • 8HARJAI K J ,Stone G W,GRINES C L ,et al.Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein II b /II1 a inhibitors [ J ]. Am J Cardiol, 2007,99 (2) : 202 - 207.
  • 9石秀英,郑兴,陈少萍,唐念中,叶忠.PCI术后是否抗凝治疗的临床疗效比较[J].现代生物医学进展,2013,13(3):486-491. 被引量：1
  • 10马丽萍,杨雅薇,李攀,陈韬,刘宇,柳俊梅.经皮冠状动脉介入围术期抗血小板药物的选择[J].药学服务与研究,2014,14(4):241-244. 被引量：2

引证文献1

二级引证文献3

新疆医学
2011年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部